Congrats to Peter Kim from our branch Surgery Branch for this Cancer Immunology Research study - TCRs targeting mutant TP53 which is widely mutated in cancer. Also the 1st case report of genetically engineered anti mutant-P53 TCR to treat breast cancer aacrjournals.org/cancerimmunolr…

Important to note that whether or not there is broad clinical efficacy - P53 neoantigens are widely immunogenic - including R175H what the patient was treated with (contrary to what people have proposed recently).

Sri Krishna The recent report you refer to was based largely on in silico predictions. The authors of that report have not been able to articulate how these empiric data demonstrating that the R175H hotspot is a bona fide cancer rejection antigen can be reconciled with their predictions.